» Articles » PMID: 36800957

Using the Emotional Functioning in Clinical Practice to Detect Psychological Distress in Patients with Advanced Thoracic and Colorectal Cancer

Abstract

Purpose: Patients with advanced cancer suffer significant decline of their psychological state. A rapid and reliable evaluation of this state is essential to detect and treat it and improve quality of life. The aim was to probe the usefulness of the emotional function (EF) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EF-EORTC-QLQ-C30) to assess psychological distress in cancer patients.

Methods: This is a multicenter, prospective, observational study involving 15 Spanish hospitals. Patients diagnosed with unresectable advanced thoracic or colorectal cancer were included. Participants completed the Brief Symptom Inventory 18 (BSI-18), the current the gold standard, and the EF-EORTC-QLQ-C30 to assess their psychological distress prior to initiating systemic antineoplastic treatment. Accuracy, sensitivity, positive predictive value (PPV), specificity, and negative predictive value (NPV) were calculated.

Results: The sample comprised 639 patients: 283 with advanced thoracic cancer and 356 with advanced colorectal cancer. According to the BSI scale, 74% and 66% displayed psychological distress with an EF-EORTC-QLQ-C30 accuracy of 79% and 76% in detecting psychological distress in individuals with advanced thoracic and colorectal cancer, respectively. Sensitivity was 79 and 75% and specificity was 79 and 77% with a PPV of 92 and 86% and a NPV of 56 and 61% (scale cut-off point, 75) for patients with advanced thoracic and colorectal cancer, respectively. The mean AUC for thoracic cancer was 0.84 and, for colorectal cancer, it was 0.85.

Conclusion: This study reveals that the EF-EORTC-QLQ-C30 subscale is a simple and effective tool for detecting psychological distress in people with advanced cancer.

Citing Articles

Global research trends on gastrointestinal cancer and mental health (2004-2024): a bibliographic study.

Han W, Wang T, He Z, Wang C, Hui Z, Lei S Front Med (Lausanne). 2025; 12:1515853.

PMID: 39935799 PMC: 11811116. DOI: 10.3389/fmed.2025.1515853.


Psychological distress and coping strategies in breast cancer patients under neoadjuvant therapy: A systematic review.

Omari M, Amaadour L, El Asri A, Benbrahim Z, Mellas N, El Rhazi K Womens Health (Lond). 2024; 20:17455057241276232.

PMID: 39287572 PMC: 11409301. DOI: 10.1177/17455057241276232.


Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.

Fraterman I, Reijers I, Dimitriadis P, Broeks A, Gonzalez M, Menzies A Nat Med. 2023; 29(12):3090-3099.

PMID: 37957378 DOI: 10.1038/s41591-023-02631-x.

References
1.
Annunziata M, Muzzatti B, Flaiban C, Gipponi K, Carnaghi C, Tralongo P . Long-term quality of life profile in oncology: a comparison between cancer survivors and the general population. Support Care Cancer. 2017; 26(2):651-656. DOI: 10.1007/s00520-017-3880-8. View

2.
Marzorati C, Monzani D, Mazzocco K, Pavan F, Monturano M, Pravettoni G . Dimensionality and Measurement Invariance of the Italian Version of the EORTC QLQ-C30 in Postoperative Lung Cancer Patients. Front Psychol. 2019; 10:2147. PMC: 6792474. DOI: 10.3389/fpsyg.2019.02147. View

3.
Calderon C, Ferrando P, Lorenzo-Seva U, Hernandez R, Oporto-Alonso M, Jimenez-Fonseca P . Factor structure and measurement invariance of the Brief Symptom Inventory (BSI-18) in cancer patients. Int J Clin Health Psychol. 2020; 20(1):71-80. PMC: 6994770. DOI: 10.1016/j.ijchp.2019.12.001. View

4.
Ketelaers S, van Heinsbergen M, Orsini R, Vogelaar F, Konsten J, Nieuwenhuijzen G . Functional Bowel Complaints and the Impact on Quality of Life After Colorectal Cancer Surgery in the Elderly. Front Oncol. 2022; 12:832377. PMC: 8886503. DOI: 10.3389/fonc.2022.832377. View

5.
Williams A, Khan C, Heckler C, Barton D, Ontko M, Geer J . Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis. Breast Cancer Res Treat. 2021; 187(1):275-285. PMC: 8080260. DOI: 10.1007/s10549-020-06067-6. View